Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter J Tonge

Showing results (1-10 of 169) with videos related to

Pageof 17
Sort By:
ACS Chemical Neuroscience|June 23, 2017
Drug-Target Kinetics in Drug DiscoveryPeter J Tonge
ACS Infectious Diseases|March 13, 2019
Quantifying the Interactions between Biomolecules: Guidelines for Assay Design and Data AnalysisPeter J Tonge
Accounts of Chemical Research|January 16, 2008
Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathwayHao Lu, Peter J Tonge
Current Opinion in Chemical Biology|July 29, 2010
Drug-target residence time: critical information for lead optimizationHao Lu, Peter J Tonge
Biochemistry|January 9, 2010
Mechanism and inhibition of the FabV enoyl-ACP reductase from Burkholderia malleiHao Lu, Peter J Tonge
Current Topics in Medicinal Chemistry|January 31, 2012
Targeting InhA, the FASII enoyl-ACP reductase: SAR studies on novel inhibitor scaffoldsPan Pan, Peter J Tonge
Current Opinion in Chemical Biology|July 19, 2018
Editorial overview: Next generation therapeuticsAdrian Whitty, Peter J Tonge
Current Opinion in Chemical Biology|April 29, 2019
Pharmacokinetic-pharmacodynamic models that incorporate drug-target binding kineticsFereidoon Daryaee, Peter J Tonge
British Journal of Pharmacology|February 12, 2026
Only time will tell: Modelling the kinetics of covalent inhibitorsMadeeha I Ali, Peter J Tonge
Proceedings of the National Academy of Sciences of the United States of America|November 19, 2003
The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistanceRicha Rawat, Adrian Whitty, Peter J Tonge
Pageof 17

Showing results (1-10 of 169) with videos related to

Sort By:
Pageof 17
ACS Chemical Neuroscience|June 23, 2017
Drug-Target Kinetics in Drug DiscoveryPeter J Tonge
ACS Infectious Diseases|March 13, 2019
Quantifying the Interactions between Biomolecules: Guidelines for Assay Design and Data AnalysisPeter J Tonge
Accounts of Chemical Research|January 16, 2008
Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathwayHao Lu, Peter J Tonge
Current Opinion in Chemical Biology|July 29, 2010
Drug-target residence time: critical information for lead optimizationHao Lu, Peter J Tonge
Biochemistry|January 9, 2010
Mechanism and inhibition of the FabV enoyl-ACP reductase from Burkholderia malleiHao Lu, Peter J Tonge
Current Topics in Medicinal Chemistry|January 31, 2012
Targeting InhA, the FASII enoyl-ACP reductase: SAR studies on novel inhibitor scaffoldsPan Pan, Peter J Tonge
Current Opinion in Chemical Biology|July 19, 2018
Editorial overview: Next generation therapeuticsAdrian Whitty, Peter J Tonge
Current Opinion in Chemical Biology|April 29, 2019
Pharmacokinetic-pharmacodynamic models that incorporate drug-target binding kineticsFereidoon Daryaee, Peter J Tonge
British Journal of Pharmacology|February 12, 2026
Only time will tell: Modelling the kinetics of covalent inhibitorsMadeeha I Ali, Peter J Tonge
Proceedings of the National Academy of Sciences of the United States of America|November 19, 2003
The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistanceRicha Rawat, Adrian Whitty, Peter J Tonge
Pageof 17